The cyclin-dependent kinase 4/6 (CDK4/6) kinase is dysregulated in melanoma, highlighting it as a potential therapeutic target. CDK4/6 inhibitors are being evaluated in trials for melanoma and additional cancers. While beneficial, resistance to therapy is a concern, and the molecular mechanisms of such resistance remain undefined. We demonstrate that reactivation of mammalian target of rapamycin 1 (mTORC1) signaling through increased expression of the amino acid transporter, solute carrier family 36 member 1 (SLC36A1), drives resistance to CDK4/6 inhibitors. Increased expression of SLC36A1 reflects two distinct mechanisms: (i) Rb loss, which drives SLC36A1 via reduced suppression of E2f; (ii) fragile X mental retardation syndrome-associated protein 1 overexpression, which promotes SLC36A1 translation and subsequently mTORC1. Last, we demonstrate that a combination of a CDK4/6 inhibitor with an mTORC1 inhibitor has increased therapeutic efficacy in vivo, providing an important avenue for improved therapeutic intervention in aggressive melanoma.
Recommended CitationYoshida, Akihiro; Bu, Yiwen; Qie, Shuo; Wrangle, John; Camp, E. Ramsay; Hazard, E. Starr; Hardiman, Gary; de Leeuw, Renée; Knudsen, Karen E.; and Diehl, J. Alan, "SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors." (2019). Department of Cancer Biology Faculty Papers. Paper 159.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License